Log in
Enquire now
‌

Blood Collection for COM/BSBS

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT06082661
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT060826610
Health Conditions in Trial
‌
Healthy
0
Trial Recruitment Size
5,0000
Trial Sponsor
University of Central Florida
University of Central Florida
0
Clinical Trial Start Date
June 23, 2022
0
Primary Completion Date
2027
0
Study Completion Date
2027
0
Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Other0
Observational Study Perspective
Other0
Participating Facility
University of Central Florida
University of Central Florida
0
Official Name
Blood Collection for Use With Translational, Biomedical Research at UCF College of Medicine and Burnett School of Biomedical Sciences0
Last Updated
October 13, 2023
0
Study summary

The objective of this biospecimen collection protocol is the acquisition of blood from adult volunteers. These biospecimens will be transferred to the College of Medicine (COM)/Burnett School of Biomedical Sciences (BSBS) research scientists and their research teams for testing according to their separate IRB-approved/exempted protocols. These separate IRBapproved protocols cannot be for genetic testing.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Blood Collection for COM/BSBS

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.